FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) is aiming to maximize the product value of the "Conversational Dementia Diagnosis Support AI Program", including further strengthening of domestic business. Also, we will start a global alliance strategy.

　FRONTEO started clinical trials of the conversational dementia diagnosis support AI program in April 2021 as originally planned, and is currently aiming to obtain manufacturing and marketing approval in Japan.In June, we signed a global license agreement with our collaborative research partner Keio Gijuku (location: Minato-ku, Tokyo) to create an environment for expanding business related to this device overseas. FRONTEO aims to make the best use of the characteristics of this device as a performance-evolved AI (AI medical device that can improve performance and add functions): (4) Selection of new development / sales partners in Japan and overseas, (6) Others We have begun to build a new system to maximize product value, such as strengthening alliances with AI companies and IT companies, and (XNUMX) expanding functions and expanding indications.

　Since June 2020, the conversational dementia diagnosis support AI program has entered into a business alliance agreement with Kyowa Yakuhin Kogyo Co., Ltd. regarding development and sales in Japan. As a result of repeated discussions in consideration of the business strategies of both companies, we have agreed to terminate this agreement in anticipation of further development of both companies.

　FRONTEO aims to contribute to the treatment of dementia in the world as an AI medical device originating in Japan, and will contribute to the development of AI medical devices in the world.

　Although the impact of this matter on the Company's business results for the current fiscal year is minor, we will promptly announce any reasons that should be disclosed in the future.

■ About conversational dementia diagnosis support AI program　URL: https://lifescience.fronteo.com/aidevice/dementia/

The conversational dementia diagnosis support AI program uses FRONTEO's original natural language analysis AI "Concept Encoder (trademark: concept encoder, reading: concept encoder)" for daily conversation between the patient and the doctor for about 5 to 10 minutes. It is an AI medical device that can screen for cognitive dysfunction, and has been in clinical trials since April 2021. FRONTEO believes that this device can contribute to the progress of digital medical care such as telemedicine and the efficiency and standardization of medical care, in addition to measures against dementia, which is an important issue in Japan, which is facing a super-aging society. I am.Patent registration number: Patent No. 4

■FRONTEOabout　URL: https://www.fronteo.com/

FRONTEO uses the in-house developed AI engine "KIBIT" and "concept encoder" specializing in natural language processing to extract meaningful and important information from a huge amount of text data to support corporate business. A data analysis company. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support international litigation of companies. Has been deployed.Based on the AI ​​technology cultivated in the legal tech business, we expanded the business field to the life science field, business intelligence field, and economic security from 8, and by using AI to "turn text data into knowledge" , Drug discovery support, dementia diagnosis support, financial / personnel / sales support, etc., contributing to solving various corporate issues. Listed on TSE Mothers on June 2014, 2007. January 6, 26 Obtained a first-class medical device manufacturing and sales license (permit number: 2021B1X13).The capital is 13 thousand yen (as of March 1, 10350).

* FRONTEO, KIBIT, and concept encoder are registered trademarks of FRONTEO in Japan.